• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2001 Fiscal Year Final Research Report Summary

THE ROLE OF VITAMN K2 ON THE MECHANISM OF OSTEOPENIA INDUCED BY PHENYTOIN ADMINISTRATION

Research Project

Project/Area Number 12671796
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Functional basic dentistry
Research InstitutionOKAYAMA UNIVERSITY

Principal Investigator

ONODERA Kenji  DEPARTMENT OF DENTAL PHARMACOLOGY, OKAYAMA UNIVERSITY, GRADUATE SCHOOL OF MEDICINE AND DENTISTRY, ASSOCIATED PROFESSOR, 大学院・医歯学総合研究科, 助教授 (40133988)

Co-Investigator(Kenkyū-buntansha) SOGAWA Norio  DEPARTMENT OF DENTAL PHARMACOLOGY, OKAYAMA UNIVERSITY, GRADUATE SCHOOL OF MEDICINE AND DENTISTRY, ASSISTANT PROFESSOR, 大学院・医歯学総合研究科, 助手 (30236153)
SAITOU Takashi  CLINICS OF DENTISTRY FOR THE DISABLED, TOHOKU UNIVERSITY DENTAL HOSPITAL, ASSOCIATED PROFESSOR, 歯学部・附属病院, 助教授 (90005108)
SHINODA Hisashi  DEPARTMENT OF DENTAL BIOLOGY, TOHOKU UNIVERSITY, GRADUATE SCHOOL OF DENTISTRY, PROFESSOR, 大学院・歯学研究科, 教授 (80014025)
Project Period (FY) 2000 – 2001
KeywordsDrug-induced osteopenia / Vitamin K2 / Phenytoin / Osteocalcin / Bone Mineral Density / Menatetrenone / Femoral bone / HPLC
Research Abstract

In this study, we investigated 1) whether the administration of phenytoin induced bone loss ; and 2) whether menatetrenone could prevent bone loss induced by phenytoin. For this purpose, we previously developed a procedure to measure the bone mineral density using a conventional X-ray absorptiometry method. A long-termed administration of phenytoin (20 mg/kg per day for 5 weeks) produced bone loss in the tibiae of growing rats. The values of bone mineral density (BMD) were significantly decreased in the tibial diaphysis and metaphysis in the phenytoin-treated group. We measured the serum level of vitamin K-dependent protein, osteocalcin, a marker of bone formation. The serum level of osteocalcin showed a decrease in the phenytoin-treated group compared with the vehicle-treated group. Combined administration of menatetrenone (30 mg/kg in diet per day) with phenytoin for 5 weeks prevented the reduction of BMD, and the level of osteocalcin was slightly increased. Thus, it is suggested that long-termed phenytoin exposure may inhibit bone formation concomitantly with insufficient vitamin K, Which, at least in part, contributed to bone loss in rats. Finally, these findings implicated the therapeutic usefulness of menatetrenone on a moderate degree of bone abnormality such as drug-induced osteopenia.

  • Research Products

    (13 results)

All Other

All Publications (13 results)

  • [Publications] 小野寺 憲治: "骨粗鬆症と治療薬の最新知見 -骨粗鬆症治療薬の作用点を受容体から考る"Pharm D. 4・2. 30-39 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 若林広行 他: "HPLC-白金還元・電気化学検出器を用いた生体中のビタミンK類の高感測定法"日本薬理学雑誌. 116. 43-48 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Wakabayashi H 他: "The levels of vitamin K analogues in bone and serum of osteoporotic and osteoarthritis patients determined by the high-performance liquid chromatography with ECD method"Journal of Bone and Mineral Research. Suppl.. S323 (2000)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Onodera Kenji 他: "Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats"Calcified Tissue International. 69. 109-116 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Onodera Kenji 他: "Changes in the concentration of vitaminK analogues in bone after long-term administration of zonisamide, an antiepileptic agent, in growing rats"Japanese Journal of Pharmacology. Suppl. 236 (2001)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Onodera Kenji 他: "Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone miner al density in the tibiae of growing rats"Life Sciences. 70(13). 1533-1542 (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Takahashi, A., Onodera, K., Shinoda, H., Mayanagi, H.: "Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin showed bone resorption in cultured neonatal mouse calvaria."Japanese Journal of Pharmacology. 82 (1). 82-84 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Wakabayashi H., Onodera K.: "Sensitive determination of vitamin K analogues in biological samples by high-performance liquid chromatography using platinum catalyst reduction and electrochemical detection."Folia Fharmacologia Japonica. 116. 43-48 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Onodera, K.: "Recent overview of osteoporosis and 1st pharmacotherapy"Pharm D. 4 (2). 30-39 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] 0nodera, K., Shinoda, H., Zushida, Ko., Taki, R., Kamei, J.: "Antinociceptive effect induced intraperitoneal administration of vitamine K2 (menatetrenone) in ICR mice."LifeSciences. 68 (1). 91-97 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Onodera., X., Zushida, Ko., and Kamei., J.: "Antinociceptive effect of vitamine K2 (menatetrenone) in diabetic mice."Japanese Journal of Pharmacology. 85. 335-337 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Onodera, K., Takahashi, A., Mayanagi, S., Wakabayashi, H., Kamei, J., Shinoda, H.: "Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats"Calcified Tissue Internatioanal. 69. 109-116 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Onodera, K., Takahashi, A., Sakurada, S., Okano, Y.: "Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats."LifeSciences. 70 (13). 1533-1542 (2002)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2003-09-17  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi